Medplus Health Services Limited
All news and filings related to Medplus Health Services Limited.
View all news & filings- Low impact
Medplus Health Services Revises Earnings Call Link for Q3 FY26 Results
Medplus Health Services Limited has revised the joining link for its earnings call scheduled for February 02, 2026, to discuss the unaudited financial results for the quarter ended December 31, 2025. The updated link and dial-in details are now available on the company's website and stock exchange websites.
Read the summary - Low impact
Medplus Health Services Schedules Earnings Call for Q3 FY26 on Feb 2
Medplus Health Services Limited will hold an earnings call on February 2, 2026, at 16:00 IST to discuss its unaudited financial results for the quarter ended December 31, 2025. Joining details will be available on the company and exchange websites.
Read the summary - Low impact
Medplus Subsidiary's Drug Licenses Suspended for Two Days in Karnataka & Telangana
Medplus Health Services Limited's subsidiary, Optival Health Solutions Private Limited, received two suspension orders for drug licenses of stores in Karnataka and Telangana. The suspensions are for two days each, effective January 19, 2026, with an estimated revenue loss of ₹1.02 lacs and ₹1.77 lacs respectively.
Read the summary - Low impact
Medplus Subsidiary's Drug License Suspended for 5 Days in Maharashtra
Medplus Health Services Limited's subsidiary, Optival Health Solutions Private Limited, has had a drug license for a store in Bhandara, Maharashtra, suspended for five days. The suspension is due to alleged violations of the Drugs and Cosmetics Act and Rules. This is expected to result in a revenue loss of approximately ₹2.06 lakh.
Read the summary - Low impact
Medplus Subsidiary Receives Six Drug License Suspension Orders
Medplus Health Services Limited's subsidiary, Optival Health Solutions Private Limited, has received six drug license suspension orders for its stores in Karnataka and Telangana. The suspensions range from one to four days and are expected to cause a total potential revenue loss of approximately ₹4.49 lacs.
Read the summary - Low impact
Medplus Health Services to Attend Investor Meetings in February 2026
Medplus Health Services Limited's KMP will attend investor meetings in February 2026. These include the Nuvama Investor Conference (Feb 9), Axis Capital's Flagship India Conference (Feb 10), and Kotak Chasing Growth 2026 (Feb 26). No UPSI will be disclosed.
Read the summary - Low impact
Medplus Subsidiary's Karnataka Store Drug License Suspended for 2 Days
Medplus' subsidiary, Optival Health Solutions, had a Karnataka store's drug license suspended for two days. The suspension, effective January 10, 2026, is due to alleged violations of the Drugs and Cosmetics Act. The company anticipates a revenue loss of approximately ₹0.74 lacs.
Read the summary - Low impact
Medplus Health Services Files SEBI Compliance Certificate for Q3 FY26
MedPlus Health Services Limited submitted a certificate for the quarter ended December 31, 2025, as per SEBI (Depositories and Participants) Regulations, 2018. The certificate confirms details of securities dematerialization/rematerialization and has been filed with stock exchanges.
Read the summary - Low impact
Medplus Subsidiary Receives One-Day Drug License Suspension Order in Karnataka
Medplus Health Services Limited's subsidiary, Optival Health Solutions, received a one-day drug license suspension for a store in Karnataka. The order was received on January 02, 2026, and is expected to result in a revenue loss of approximately ₹0.23 lacs.
Read the summary - Low impact
Medplus Subsidiary Receives 7-Day Drug License Suspension in Andhra Pradesh
Medplus subsidiary, Optival Health Solutions, received a 7-day suspension order for its drug license at a store in Gollapudi, Andhra Pradesh. The order was received on December 31, 2025. The company anticipates a revenue loss of approximately ₹2.10 lakhs.
Read the summary - Low impact
Medplus Promoters Release Pledge on 41.7 Lakh Shares
Agilemed Investments Private Limited, a promoter of Medplus Health Services Limited, unpledged 41,71,970 equity shares on December 24, 2025. This action is part of the company's debt refinancing through NCDs. The promoter group's aggregate pledge has now reduced to 24.48%.
Read the summary - Low impact
Medplus Subsidiary's Drug License Suspended for One Day in Telangana
Medplus Health Services Limited's subsidiary, Optival Health Solutions Private Limited, had one store's drug license suspended for one day in Telangana. The suspension, effective December 30, 2025, is expected to result in a revenue loss of approximately ₹1.19 lacs.
Read the summary - Medium impact
Medplus Subsidiary Optival Receives Two Drug License Suspension Orders
Medplus subsidiary Optival Health Solutions received two drug license suspension orders. A Telangana store faces a 3-day suspension (potential loss ₹1.69 lacs), and a Maharashtra store faces a 7-day suspension (potential loss ₹3.85 lacs). The orders are related to alleged violations of the Drugs and Cosmetics Act.
Read the summary - Low impact
Medplus Subsidiary Receives Three Drug License Suspensions in Karnataka
Medplus subsidiary Optival Health Solutions received three drug license suspension orders in Karnataka for stores in Jayanagar, T R Nagar, and Shiggon Haveri. The suspensions are for three days each and were effective from December 23, 2025, with potential revenue losses estimated up to ₹2.29 lacs.
Read the summary - Low impact
Medplus Health Services Closes Trading Window from Jan 1, 2026 for Q3 FY26 Results
Medplus Health Services Limited announced a trading window closure from January 1, 2026, until 48 hours post the declaration of Q3 FY26 un-audited financial results. The board meeting date for considering these results will be announced later.
Read the summary - Low impact
Medplus Subsidiary Optival Health Solutions Receives Drug License Suspension Order in Maharashtra
Medplus Health Services Limited's subsidiary, Optival Health Solutions Private Limited, has had its drug license suspended for a store in Ahmednagar, Maharashtra, for ten days. The suspension, effective from December 19, 2025, is due to alleged violations of the Drugs and Cosmetics Act and Rules. A potential revenue loss of ₹2.00 lacs is anticipated.
Read the summary - Medium impact
Medplus Promoters Execute Debenture Trust Deed for ₹175 Crore NCD Issuance
Medplus promoters executed a Debenture Trust Deed on December 12, 2025, for issuing Non-Convertible Debentures (NCDs) up to ₹175 crore. This is for refinancing existing debt. The promoter share pledge will temporarily increase to 27.96% from 23.91% and is expected to reduce to 24.48% post-refinancing.
Read the summary - Medium impact
Medplus Subsidiary Receives 3 Drug License Suspension Orders in Maharashtra
Medplus' subsidiary, Optival Health Solutions, received three drug license suspension orders in Maharashtra for its stores. The suspensions, lasting five days each, are for alleged violations of the Drugs and Cosmetics Act. Potential revenue loss is estimated at ₹5.96 lakhs (Amravati), ₹2.57 lakhs (Nagpur), and ₹1.64 lakhs (Nagpur). Orders were received on December 13, 2025.
Read the summary - Low impact
Medplus Subsidiary's Drug License Suspended for 5 Days in Karnataka
MedPlus Health Services Limited's subsidiary, Optival Health Solutions Private Limited, received a 5-day suspension order for its drug license in Karnataka. The suspension is for a store at Ganganagar Bus Stop and is due to alleged violations of the Drugs and Cosmetics Act. The company anticipates a revenue loss of ₹2.40 lacs.
Read the summary - Medium impact
Medplus Subsidiary Optival Receives Favorable High Court Order on ₹43.45 Crore Tax Dispute
Medplus Health Services Limited's subsidiary, Optival Health Solutions, received a favorable High Court order on November 21, 2025, disposing of a writ petition. The case involved a disputed tax amount of ₹43.45 Crores for AY: 2020-21. The High Court's decision has no financial impact on the company.
Read the summary - Low impact
MedPlus Subsidiary's Karnataka Store Drug License Suspended for One Day
MedPlus Health Services Limited's subsidiary, Optival Health Solutions, received a one-day suspension order for a Drug License for a store in Hubli, Karnataka. The suspension, effective December 9, 2025, is due to alleged violations of the Drugs and Cosmetics Act and Rules. Potential revenue loss is estimated at ₹0.58 lakhs.
Read the summary - Low impact
Optival Health Solutions Receives Suspension Order for Drug License
MedPlus subsidiary, Optival Health Solutions, receives a two-day suspension order for a drug license in Telangana, resulting in a potential revenue loss of ₹0.87 lakh.
Read the summary - Low impact
Optival Health Solutions Drug License Suspension in Maharashtra
MedPlus subsidiary, Optival Health Solutions, faces a 25-day drug license suspension in Maharashtra, potentially causing a ₹5.87 lakh revenue loss due to non-compliance with drug regulations.
Read the summary - Low impact
Optival Health Solutions, Medplus subsidiary, receives suspension order for drug license
Medplus subsidiary, Optival Health Solutions, receives a 15-day suspension order for a drug license in Maharashtra, potentially causing a revenue loss of ₹6 lakh.
Read the summary - Low impact
Optival Health Solutions, subsidiary of Medplus, receives suspension order for drug license.
Medplus subsidiary, Optival Health Solutions, receives suspension order for drug license in Telangana, leading to potential revenue loss of ₹1.43 lakh.
Read the summary - Low impact
Medplus Health Services: Subsidiary Faces Drug License Suspensions
Medplus subsidiary, Optival Health Solutions, faces drug license suspensions at two store locations, potentially impacting revenue by ₹1.73 lakh.
Read the summary - Low impact
Medplus Health Services: Subsidiary Faces Drug License Suspension
Medplus Health Services' subsidiary, Optival Health Solutions, received a two-day suspension order for a drug license in Telangana, potentially causing a revenue loss of ₹1.31 lakh.
Read the summary - Low impact
Subsidiary Optival Health Solutions Receives Suspension Order for Drug License
Medplus Health Services' subsidiary, Optival Health Solutions, receives a two-day suspension order for a drug license in Telangana, potentially leading to a revenue loss of ₹0.72 lakh.
Read the summary - Low impact
Drug License Suspension for Medplus Subsidiary, Optival Health Solutions
Medplus subsidiary, Optival Health Solutions, faces a one-day drug license suspension for a store in Karnataka, leading to an estimated revenue loss of ₹0.33 lakh.
Read the summary - Low impact
Optival Health Solutions Receives Suspension Orders for Drug Licenses
Medplus subsidiary, Optival Health Solutions, receives suspension orders for drug licenses in Karnataka and Telangana, leading to potential revenue losses.
Read the summary - Low impact
Optival Health Solutions Receives Suspension Orders for Drug License
Optival Health Solutions, a Medplus subsidiary, received suspension orders for a drug license in Karnataka, leading to a potential revenue loss of ₹3.49 lakh.
Read the summary - Low impact
Medplus subsidiary faces 3-day drug license suspension for a Karnataka store
Medplus subsidiary, Optival Health Solutions, received a 3-day drug license suspension for a Karnataka store, with a potential revenue loss of ₹1.08 lakhs.
Read the summary - Low impact
Medplus Health Services to attend Avendus Investor Conference on November 18-19, 2025
Medplus KMP will attend the Avendus Investor Conference in Mumbai on November 18-19, 2025, for physical meetings. No UPSI will be disclosed, and the schedule may change.
Read the summary - Low impact
Medplus Health Services: Subsidiary Faces Drug License Suspension
Medplus Health Services' subsidiary, Optival Health Solutions, faces a seven-day suspension of its drug license for a store in Andhra Pradesh, potentially resulting in a revenue loss of ₹3.82 lakh.
Read the summary - Low impact
Medplus subsidiary receives 3-day drug license suspension for a Telangana store
Medplus's subsidiary, Optival Health Solutions, faced a 3-day drug license suspension for a Telangana store due to a violation, potentially losing ₹1.73 lakh in revenue.
Read the summary - High impact
Medplus Health Services Releases Q2 FY'26 Earnings Call Transcript, Highlights Revenue and Store Growth
Medplus released its Q2 FY'26 earnings call transcript, reporting ₹1,679.30 crore revenue and ₹88.70 crore EBITDA. The company expanded its store network, grew diagnostics, and expects SSSG to reach high-single digits.
Read the summary - Low impact
Medplus Health Services Limited Submits Audio Recording of Earnings Call
Medplus Health Services Limited has submitted the audio recording of the earnings call held on November 3, 2025, to discuss the financial results for the quarter and half year ended September 30, 2025.
Read the summary - Low impact
Optival Health Solutions Drug License Suspended
Medplus Health Services' subsidiary, Optival Health Solutions, faces a 21-day drug license suspension for a store in Maharashtra, leading to a potential revenue loss of ₹4.34 lakh.
Read the summary - Medium impact
Medplus Health Services Secures Stay Orders Against Suspension in Maharashtra
Medplus Health Services obtained two Stay Orders against a suspension in Nagpur and Amravati, Maharashtra, reversing previous regulatory action.
Read the summary - Low impact
Medplus Subsidiary Faces 7-Day Drug License Suspension in Andhra Pradesh
Medplus's subsidiary, Optival Health Solutions, received a 7-day drug license suspension for an Andhra Pradesh store on October 31, 2025, due to a regulatory violation, with a potential revenue loss of ₹1.75 lakh.
Read the summary - Low impact
Medplus Health Services Board Approves Q2 & H1 FY26 Unaudited Financial Results
Medplus Health Services Board approved un-audited Standalone and Consolidated Financial Results for Q2 and H1 ended September 30, 2025. The results were published in newspapers on November 1, 2025.
Read the summary - Medium impact
Medplus Health Services Investor Presentation on Q2 FY26 Results
Medplus Health Services announced its investor presentation for Q2 FY26 results, with the earnings call scheduled for November 03, 2025. Key highlights include revenue growth, improved gross margin, and expansion of store network.
Read the summary - Medium impact
Medplus Health Services Limited Approves Un-audited Financial Results
Medplus Health Services Limited approved the un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 in their board meeting held on October 31, 2025.
Read the summary - Low impact
Optival Health Solutions Private Limited, a subsidiary of MedPlus, receives suspension orders for Drug License
MedPlus subsidiary, Optival Health Solutions, receives drug license suspension orders from Karnataka and Telangana, leading to potential revenue losses of ₹1.12 lakh and ₹0.39 lakh respectively.
Read the summary - Low impact
Medplus Health Services: Subsidiary Receives Drug License Suspension Orders
Medplus subsidiary, Optival Health Solutions, received two drug license suspension orders leading to potential revenue losses of ₹1.12 lakh and ₹1.71 lakh respectively.
Read the summary - Low impact
Medplus Subsidiary Receives Drug License Suspension for Two Telangana Stores
Medplus subsidiary received two drug license suspension orders for stores in Telangana due to violations, resulting in a minor potential revenue loss of approximately ₹0.48 lakh and ₹1.28 lakh.
Read the summary - Low impact
Optival Health Solutions Drug License Suspended
Optival Health Solutions, a Medplus subsidiary, had a drug license suspended for three days in Telangana, leading to a potential revenue loss of ₹0.22 lakh.
Read the summary - Low impact
Optival Health Solutions faces drug license suspension for a store.
Optival Health Solutions, a subsidiary of Medplus, faces a seven-day drug license suspension for a store in Andhra Pradesh, potentially resulting in a revenue loss of ₹1.75 lakh.
Read the summary - Low impact
Subsidiary Optival Health Solutions faces 15-day drug license suspension for Karnataka store
Medplus's subsidiary, Optival Health Solutions, received a 15-day drug license suspension for a Karnataka store due to a violation, with a potential revenue loss of ₹10.15 lakhs.
Read the summary - Medium impact
Medplus Subsidiary Optival Health's Credit Ratings Reaffirmed by CareEdge Ratings
Medplus Health Services announced that CareEdge Ratings reaffirmed the credit ratings for its subsidiary, Optival Health Solutions Private Limited, for both long-term and short-term bank facilities.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio